

Cover Letter

Dear Editor

On behalf of my co-authors, I submit a research communication for your review, entitled:

“Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day-7

Interim Analysis of an Ongoing Clinical Trial”

We join you in the hope for a rapid global recovery from COVID-19, as we explore a different therapeutic modality. The authors have not published any related papers from this same study to any other journal.

Sincerely,



Mohammad Khan MD PhD FACRO
Associate Professor
Director, Radiation Immuno-Oncology
Co-Leader, Immuno-Oncology
Winship Cancer Institute, Emory University Hospital
1365 Clifton Road NE
Atlanta GA 30345
drkhurram2000@gmail.com
Phone: (404) 778-3473

Abstract

Background: Individuals with advanced age and comorbidities face higher risk of death from COVID-19, especially once ventilator-dependent. Respiratory decline in COVID-19 is mediated by a pneumonic aberrant immune cytokine storm. Low-dose radiation was used to treat pneumonia in the pre-antibiotic era. Radiation immunomodulatory effects may improve outcomes in COVID-19.

Methods: We performed a single-institution phase I/II trial evaluating the safety and efficacy of single-fraction, low-dose, whole-lung radiation for COVID-19 pneumonia. Eligible patients were hospitalized, had radiographic pneumonic infiltrates, required supplemental oxygen, and were clinically deteriorating.

Results: Of nine patients screened, five were treated with whole-lung radiation from April 23-28, 2020 and followed for 7 days. Median age was 90 (range 64-94); four were nursing home residents with multiple comorbidities. Within 24 hours of radiation, three patients (60%) weaned from supplemental oxygen to ambient air, four (80%) exhibited radiographic improvement, and median Glasgow coma score improved from 10 to 14. A fourth patient (80% overall recovery) weaned from oxygen at hour 96. Mean time to clinical recovery was 35 hours. There were no acute skin, pulmonary, GI, GU toxicities.

Conclusions: In a small pilot trial of five oxygen-dependent patients with COVID-19 pneumonia, low-dose whole-lung radiation led to rapid improvement in clinical status, encephalopathy, and radiographic infiltrates without acute toxicity or worsening the cytokine storm. Low-dose whole-lung radiation appears to be safe, shows early promise of efficacy, and warrants larger prospective trials.

NCT: 04366791

Title Page

Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day-7 Interim Analysis of an Ongoing Clinical Trial

Clayton B. Hess MD MPH^{1,7}, Zachary S. Buchwald MD PhD^{1,7}, William Stokes MD^{1,7}, Jeffrey M. Switchenko PhD MS^{2,7}, Tahseen H. Nasti PhD³, Brent D. Weinberg MD⁵, James P. Steinberg MD⁴, Karen D. Godette MD^{1,7}, David Murphy MD PhD⁶, Rafi Ahmed PhD^{3,7}, Walter J. Curran Jr MD^{1,7}, Mohammad K. Khan MD PhD^{1,7}.

Departments of ¹Radiation Oncology, ²Biostatistics and Bioinformatics, ³Microbiology and Immunology, ⁴Infectious Disease, ⁵Diagnostic Radiology, Pulmonary Critical Care ⁶. Winship Cancer Institute⁷. Emory University. Atlanta GA

Running Title: Low-Dose Lung Radiation in COVID-19

*Corresponding Author:

Mohammad K Khan, MD PhD FACRO
Associate Professor, Radiation Oncology
Winship Cancer Institute
Emory University Hospital
1365 Clifton Road NE
Atlanta GA 30345
drkhurram2000@gmail.com
Phone: (404) 778-3473

Funding: None

Lay Summary: Researchers at Emory University have completed treatment of cohort 1 of a pilot trial of low-dose lung irradiation for COVID-19 pneumonia. Five residents of nursing or group homes with COVID-19 outbreaks were hospitalized after testing positive for COVID-19. Each had pneumonia visible on chest x-ray, required supplemental oxygen, and had clinically declined. A single treatment of low-dose (1.5 Gy) radiation to both lungs was delivered over 10-15 minutes. Within 24 hours, four patients rapidly improved their breathing, recovering at an average of 1.5 days (range 3 to 96 hours), and had either been discharged (three) or were preparing for discharge (one) by day 14. Blood tests and repeat imaging confirmed that low-dose radiation appeared safe and effective in reducing their COVID-19 symptoms. Further trials are warranted.

Introduction

Individuals with advanced age and comorbidities face a higher risk of death from COVID-19, especially once ventilator-dependent, precipitated by an immune cytokine storm in the lungs.¹⁻³ Lymphocytes, a mediator of cytokine storms, are exquisitely sensitive to ionizing radiation.⁴ Low doses of radiation therapy (LD-RT) were successfully used to treat patients with infectious processes during the first half of the 20th century, including pneumonia.⁵ It is conceivable that focal immunosuppression with LD-RT may reduce pulmonary inflammation associated with COVID-19 pneumonia and thereby alter the clinical course of infected patients.

Methods

Trial Design

The Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-day Treatment for COVID-19 (RESCUE 1-19) trial is an ongoing investigator-initiated trial exploring safety and efficacy of single-fraction, low-dose, whole-lung radiation for hospitalized, oxygen-dependent patients with COVID-19 pneumonia (Clinical Trial Registration Number NCT04366791). The protocol was approved by the Emory University Institutional Review Board, and all human participants or their surrogate representatives gave written informed consent. Eligibility required patients to be hospitalized with a positive nasopharyngeal swab for COVID-19, have radiographic pneumonic consolidations, require oxygen supplementation, and be clinically deteriorating (i.e. mentation, oxygenation, dyspnea). Exclusion criteria included receipt of any COVID-directed drug therapy within one day before or three days following LD-RT. Intubated patients were deemed unstable for transport and not treated. Patients received a single-fraction radiation dose of 1.5 Gy to the bilateral lungs, delivered via an anterior-posterior beam configuration. The primary endpoint was safety as assessed by clinical, radiographic, and inflammatory marker response. Clinical recovery was defined as the first day a subject was discharged or weaned from supplemental oxygen.

Results

Between April 23-28, 2020, nine study candidates were evaluated. Of these, one died before enrollment, one did not meet severity criteria, and seven enrolled. Of these, two were intubated before LD-RT (one died), and five were treated with LD-RT. Table 1 outlines demographic and clinical characteristics of treated patients at admission. Median age was 90 (range 64-94). Four had been admitted from nursing homes with COVID-19 outbreaks. Comorbidity burden was high. Four were African American, and one was Caucasian. Four were female. Median Glasgow Coma Scale (GCS) score was 10 (range 9-15) at time of consent. Median Karnofsky Performance Status was 40% (range 40-80%). Median oxygen supplementation requirement at the time of LD-RT was 3 L/min (range 1.5-6). Median duration of pre-hospitalization symptoms was 4 days (range 1-7). LD-RT was delivered on median hospital day 5 (range 2-8).

During a 14-day observation period, 4 patients (80%) clinically recovered, 3 within 24 hours (Figure 1). Mean time to recovery was 1.5 days (35 hours). Mean time to discharge was 12 days for the 4 patients. Median GCS rose from 10 (range 9-15) to 14 (range 13-15) at hour 24. No acute skin, GI, cardiac, or pulmonary toxicities were noted. At day 3, 80% of assessed inflammatory biomarkers either remained stable or improved. At day 7, all but one patient with abnormal inflammatory (4/5), renal (2/3), cardiac (4/5), clotting (3/4), and hepatic (3/4) blood markers had rapidly returned to or were approaching normal levels. At day 14, all patients were alive, 3 had returned to their nursing homes, and a 4th was pending hospital discharge.

Discussion

This letter summarizes the first known use of ionizing radiation for infectious disease in the modern era and the first use in world, to author's knowledge, for patients with COVID-19. Five hospitalized, oxygen-dependent, and clinically deteriorating patients received low-dose, whole-lung radiation and experienced no acute toxicity. 80% of patients returned to breathing room air at a median time of 1.5

days. Two patients who consented to the trial rapidly deteriorated and could not receive LD-RT, yielding a cumulative response rate for the entire cohort of 4/7 (57%). No toxicities, including dermatitis, cytopenia, or worsening cytokine storm, were observed. Low-dose lung radiation appears safe and merits further evaluation to determine efficacy among patients with COVID-19 pneumonia.

Acknowledgements


We would like to acknowledge our collaborating physicians Dr. Jesse James MD, Dr. Michael Sterling MD, Dr. Charles Grodzin MD, Dr. Craig Coopersmith MD, Dr. Greg Martin MD, Dr. Marybeth Sexton MD MSC, Dr. Ramzy Rimawi MD, and Dr. Samer Melhem MD PhD for contributions and collaboration for trial accrual.

References

1. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020;395:1033-4.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
3. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. *N Engl J Med* 2020.
4. Nakamura N, Kusunoki Y, Akiyama M. Radiosensitivity of CD4 or CD8 positive human T-lymphocytes by an in vitro colony formation assay. *Radiat Res* 1990;123:224-7.
5. Calabrese EJ, Dhawan G. How radiotherapy was historically used to treat pneumonia: could it be useful today? *Yale J Biol Med* 2013;86:555-70.

Figure Legends

Figure 1. Time to Clinical Recovery (TTCR) and Oxygen Saturations 72 hours Pre and Post Radiation Therapy



| ID | Ordinal Scale for Clinical Improvement by Hospital Day | | | | | | | | | | | | | | | | | | TTCR |
|-----------|--|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----------|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | |
| Patient 1 | 5 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 18 hours |
| Patient 2 | 4 | 4 | 4 | 4 | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | - | - | - | 24 hours |
| Patient 3 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | - | - | - | - | 96 hours |
| Patient 4 | 4 | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | - | - | - | - | - | - | 3 hours |
| Patient 5 | 4 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | - | - | - | - | - | - | - | - | - | Ongoing |

1=not hospitalized. 2=hospitalized without need for oxygen or medical care. 3=hospitalized without need for oxygen. 4=hospitalized requiring low-flow supplemental oxygen. 5=hospitalized on high-flow oxygen. 6=hospitalized on mechanical ventilation 7=deceased.

Table 1. Patient Demographic and Clinical Characteristics at Time of Admission

| | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 |
|---|---------------------------------|--|--|--|---|
| Age (years) | 90s | 70s | 90s | 90s | 60s |
| Race | African American | African American | African American | Caucasian | African American |
| Gender | Female | Female | Female | Female | Male |
| Residence | Nursing Home | Nursing Home | Nursing Home | Nursing Home | Group Home |
| Charlson Comorbidity Index [Estimated 10-year survival] | 6 [21%] Age >80 PVD DM | 7 [0%] Age 60-69, COPD, CVA, one-sided weakness Dementia | 7 [0%] Age >80, prior MI, CAD, PVD, Dementia | CCI: 5 [21%] Age>80, prior MRI, CAD | CCI: 3 [77%] Age 60-69 Chronic cognitive deficit |
| Karnofsky Performance Status | Bedridden (40) | Bedridden (40) | Bedridden (40) | Occ Assistance (60) | Ambulatory (80) |
| Presenting Symptoms | Fever | Fever Dyspnea Hypoxia (80s) | Fever Dyspnea Hypoxia (80s) Low appetite Fatigue | Fever Dyspnea Hypoxia (80s) Diarrhea Confusion | Fever Dyspnea Hypoxia (80s) Diarrhea Body Aches |
| Symptom Onset Prior to Presentation | 3 days | 2 days | 4 days | 7 days | >1 week |
| COVID+ test | Hospital day 0 | Hospital day 0 | Hospital day 0 | Week prior | Week prior |
| Admission Vitals | | | | | |
| Temperature (C) | 36.8-39.8 | 36.6-38.6 | 37.5 | 36.8-37.1 | 37.6-38.7 |
| Heart Rate (bpm) | 66-79 | 80-117 | 101-120 | 94-105 | 71-118 |
| SBP (mm Hg) | 109-130 | 96-121 | 92-151 | 132-142 | 124-134 |
| DBP (mm Hg) | 51-63 | 59-70 | 52-79 | 70-78 | 83-89 |
| O2 saturation (%) | 100 | 94 | 95 | 96 | 98 |
| O2 need (L/min) | 2 NC | 3 NC | 10 NRB | 3 NC | 4 NC |
| Respiratory Rate (breath/min) | 15-21 | 19-33 | 18-26 | 16-19 | 18-26 |
| Glasgow (GCS) | 15 (E4V5M6) | 14 (E4V4M6) | 12 (E4V3M5) | 14 (E4V4M6) | 15 (E4V5M6) |
| GCS (at TOC) | 10 (E3V3M4) | 9 (E2V2M4) | 10 (E3V3M4) | 14 (E4V4M6) | 15 (E4V5M6) |
| O2 Use (L/min) at LD-RT delivery | 1.5 NC | 4 NC | 3 NC | 2 NC | 6 NC |
| Deterioration | Mental status | Mental status | Mental status | Rising O2 need | Rising O2 need |